Antagonist effect of terguride in Parkinson's disease

S. Ruggieri, F. Stocchi, F. Baronti, F. Viselli, R. Horowski, C. Lucarelli, A. Agnoli

Research output: Contribution to journalArticlepeer-review


The effects of the partial dopamine agonist terguride (9,10 transdihydrolisuride; THDL) on striatal dopamine receptors were studied by its i.v. administration to 13 patients with Parkinson's disease. Patients were maintained in a steadily mobile state with abnormal involuntary movements by a constant i.v. infusion of levodopa. Terguride showed dopamine antagonist properties in nine patients. In two of these nine patients, a decrease in dyskinesia score was observed without a concomitant worsening of parkinsonian symptoms, whereas in the remaining seven, full parkinsonian akinesia followed THDL administration. The subsequent i.v. injection of the dopamine agonist lisuride reversed THDL-induced akinesia in these seven patients. In the remaining four patients, no clinically significant motor effects were observed. These results show dopamine antagonist activity of terguride in patients with Parkinson's disease treated with Levodopa. Further studies using a wider dose titration are required to evaluate the possible role of dopamine partial agonists in the therapy of levodopa-induced dyskinesias.

Original languageEnglish
Pages (from-to)450-456
Number of pages7
JournalClinical Neuropharmacology
Issue number5
Publication statusPublished - 1991


  • Dopamine
  • Parkinson's disease
  • Partial agonists

ASJC Scopus subject areas

  • Clinical Neurology
  • Pharmacology (medical)
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)


Dive into the research topics of 'Antagonist effect of terguride in Parkinson's disease'. Together they form a unique fingerprint.

Cite this